The use of medical cannabis with other medications a review of safety and guidelines - an update
The aim of this report is to review the evidence surrounding safety of medical cannabis in combination with other medications, and relevant evidence-based guidelines. This is an update of a previous report published in April 2017, which found a single systematic review, and no evidence-based guideli...
| Main Authors: | , |
|---|---|
| Corporate Authors: | , |
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
2019, September 27, 2019
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The aim of this report is to review the evidence surrounding safety of medical cannabis in combination with other medications, and relevant evidence-based guidelines. This is an update of a previous report published in April 2017, which found a single systematic review, and no evidence-based guidelines. Evidence of limited quality from two studies of oral cannabidiol in combination with other antiepileptic drugs indicated that cannabidiol may increase serum levels of clobazam. One of these two studies also found that oral cannabidiol may increase serum levels of eslicarbazepine, topiramate, zonisamide, and rufinamide. This evidence was limited by a high risk of bias and may not be generalizable to the Canadian context. Additionally, only antiepileptic drugs were studied. No evidence-based guidelines surrounding drug interactions with medical cannabis were found |
|---|---|
| Item Description: | Replacement of The use of medical cannabis with other medications : a review of safety and guidelines / Khai Tran, Carolyn Spry. April 19, 2017 |
| Physical Description: | 1 PDF file (14 pages) illustration |